Business Development
- Strategic Alliances

Business Development: Market Assessment

There is no vaccine for the world's leading source of fungal disease: Candida.

Around eight million new cases of Candida occur each year in the USA, with 30 million people suffering from recurring infections [Ligocyte, 1999].

Patients in the USA with Candidemia spend an additional 10 days in hospital at a cost of ~$39,000 per patient [Pfizer, 2006].

While Diflucan® (Pfizer) had peak sales of US $1.2 billion in targeting fungal infections, TheraCarb’s focused market are immune-impaired patients as:

Systemic Candida infection causes death in 77% of the cases
Up to 93% of AIDS patients are affected, in which the Centers for Disease Control and Prevention (CDC) suggests all AIDS patients are candidates for vaccination

There is no cure for the world's leading form of dementia: Alzheimer's Disease.

10% of people over 65 suffer from AD including 4.5 million Americans [Pfizer Inc.]

AD forecast to become fastest growing indication in CNS market for 2004 - 2010 with CAGR 15.8% [CNS Market Outlook to 2010].

All drugs treat symptoms of AD, but not the underlying cause
34 million cases expected globally by 2025 due to aging and growing population
In the US (2000), direct and total costs estimated to be $536B and $1.75T [WHO Report 2006]

There is no cure for the often fatal disease: Amyloid A Amyloidosis.

Amyloid A (AA) Amyloidosis results in localized or systemic organ damage, fueling a mortality rate of over 90%.

Approximately 10% of people suffering from diseases such as rheumatoid arthritis, inflammatory bowel disease and chronic infections develop AA Amyloidosis.

Since AA Amyloidosis is recognized as a rare disease, it qualifies for faster FDA approval and greater market protection as a result of its Orphan Drug status.